Near-infrared Spectroscopy-based Neurofeedback as Adjunct to Mindfulness-Oriented Recovery Enhancement in Persons With Chronic Pain
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Pain Syndrome
- Sponsor
- University of Utah
- Enrollment
- 142
- Locations
- 1
- Primary Endpoint
- Blood oxygenation level dependent (BOLD) signaling
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
The primary aim of this pilot trial is to enhance the efficacy of the Mindfulness-Oriented Recovery Enhancement (MORE) intervention by adding neurofeedback (NF) of the Orbitofrontal Cortex (OFC) as an adjunct to the savoring component of MORE. We hypothesize that the use of NF to train OFC responses during savoring will amplify patients' ability to savor and thereby increase brain responsivity to natural rewards; such enhanced reward responding will in turn be associated with improvements in clinical outcomes (e.g., pain, analgesic use).
Investigators
Eligibility Criteria
Inclusion Criteria
- •≥18 years of age,
- •ability to understand and speak the English language
- •current chronic pain-related diagnosis
Exclusion Criteria
- •mindfulness training experience (e.g., participation in MBSR/MBRP)
- •neurofeedback experience
- •current cancer diagnosis
- •having a psychiatric or medical condition that precludes the ability to provide informed consent or participation in outpatient treatment (e.g., psychosis, mania, acute intoxication)
- •suicidal ideation with a plan in the past week, or a suicide attempt in the past 3 months
- •unwilling, unable, or unlikely to complete study procedures (e.g., planned major surgery, anticipated move, travel barrier)
- •communication or cognitive impairment that limits participation in group treatment or study procedures
Outcomes
Primary Outcomes
Blood oxygenation level dependent (BOLD) signaling
Time Frame: From baseline to immediately after the intervention.
Changes in blood oxygenation levels to reward cues will be assessed, and planned comparisons will be performed between subjects receiving MORE+NF vs the control conditions.
Secondary Outcomes
- Chronic pain symptoms(From baseline to 3-month follow-up.)
- Pleasant sensation ratio(From baseline to immediately after intervention.)
- Opioid misuse(From baseline to 3-month follow-up.)
- Opioid dose(From baseline to 3-month follow-up.)
- Savoring(From baseline to 3-month follow-up.)
- Pleasure ratings(From baseline to immediately after intervention.)
- Distress(From baseline to 3-month follow-up.)
- Self-transcendence(From baseline to 3-month follow-up.)
- Opioid craving(From baseline to 1-month follow-up.)
- Positive affect(From baseline to 1-month follow-up.)